NCT07163325 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT07163325
Title	EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
Recruitment	Recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Epics Therapeutics
Indications	urinary bladder cancer cervical cancer thymoma stomach cancer colorectal cancer renal cell carcinoma pancreatic cancer endometrial cancer parathyroid carcinoma lung non-small cell carcinoma urethra cancer head and neck cancer ovarian cancer sarcoma testicular cancer thyroid cancer adrenal gland cancer esophageal cancer triple-receptor negative breast cancer cholangiocarcinoma
Therapies	EP102
Age Groups:	senior \| adult
Covered Countries	NLD \| ESP \| CZE \| BEL

No variant requirements are available.